Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors

Ding YuPing; Li Hai; Zhang Wen; Xia ShiHai; Bi Xun

doi:10.3969/j.issn.1001-5256.2017.12.020

Issue 12

Dec. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(12): 2355-2360

PDF( 1638 KB)

Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors

DOI: 10.3969/j.issn.1001-5256.2017.12.020

Second Department of Gastroenterology, The Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces

Research funding:

Received Date: 2017-10-16
Published Date: 2017-12-20

Abstract

Abstract

Objective To investigate the epidemiological characteristics of nonalcoholic fatty liver disease ( NAFLD) with elevated alanine aminotransferase ( ALT) and related risk factors. Methods A total of 1007 patients with NAFLD who were admitted to The Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces from April 4, 2016 to September 13, 2016 were enrolled, and among these patients, 123 had an elevated ALT level ( higher than the upper limit of normal 50 U/L) ( elevated ALT group) and 884 had normal ALT ( normal ALT group) . A statistical analysis was performed for their general data and laboratory markers [number of peripheral blood mononuclear cells, fasting blood glucose, triglyceride ( TG) , total cholesterol ( TC) , high-density lipoprotein ( HDL) , low-density lipoprotein ( LDL) , LDL/HDL ratio, ALT, aspartate aminotransferase ( AST) , gamma-glutamyl transpeptidase ( GGT) , alkaline phosphatase ( ALP) , uric acid ( UA) , creatinine, blood urea nitrogen, urinary protein, urinary microproteins], blood pressure, body mass index ( BMI) , concomitant biliary disease, and thyroid nodules. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. A multivariate logistic regression analysis was used to identify the risk factors for elevated ALT in NAFLD patients. Results Among the 1007 patients with NAFLD, there were 752 male and 255 female patients.Of all male patients, 13. 7% ( 103/752) were in the elevated ALT group, and of all female patients, 7. 8% ( 20/255) were in the elevated ALT group; there was a significant difference in the prevalence rate between male and female patients ( χ2= 5. 552, P = 0. 018) . According to the age, the 1007 patients were divided into 20-39 year group with 242 patients, 40-59 year group with 555 patients, and 60-90 year group with 210 patients, and there was a significant difference in the proportion of patients with an elevated ALT level between these three groups ( 26. 03% vs 8. 83% vs 5. 24%, χ2= 52. 327, P < 0. 001) ; further comparison between any two groups showed that the 20-39 year group had a significantly higher proportion of patients with an elevated ALT level than the 40-59 year group and the 60-90 year group ( χ2= 39. 886 and 34. 009, both P < 0. 001) . Most patients in the elevated ALT group were young and middle-aged adults, and compared with the normal ALT group, the elevated ALT group had a significantly younger age and a significant higher BMI ( t = 7. 419 and-4. 595, both P < 0. 001) ; there were also significant differences between the two groups in UA, number of peripheral blood mononuclear cells, LDL/HDL ratio, HDL, AST, and GGT ( U = 42 942, 47 697, 48 106, 49 086, 31 938, and 36 283, all P < 0. 05) . Of all 1007 patients, 392 had NAFLD complicated by thyroid nodules, and the elevated ALT group had a significantly higher proportion of such patients than the normal ALT group ( 40. 2% vs 30. 1%, P < 0. 05) . The univariate analysis showed that male sex, age ( young and middle ages) , a high number of peripheral blood mononuclear cells, increased LDL/HDL ratio, a low level of HDL, a high level of GGT, a high BMI, and absence of thyroid nodules were associated with elevated ALT in NAFLD patients ( all P < 0. 05) . The multivariate logistic regression analysis showed that young and middle ages ( 20-39 years) , a high number of peripheral blood mononuclear cells, and a high level of GGT were independent risk factors for elevated ALT in NAFLD patients ( all P < 0. 001) . Conclusion Young and middle ages ( 20-39 years) , a high number of peripheral blood mononuclear cells, and a high level of GGT are predictive factors for elevated ALT in NAFLD patients and may have a certain value in guiding the early diagnosis of nonalcoholic steatohepatitis.
- nonalcoholic fatty liver disease,
- alanine transaminase,
- epidemiology,
- risk factors

FullText(HTML)

References(25)

References

[1]CALDWELL S, ARGO C.The natural history of non-alcoholic fatty liver disease[J].Dig Dis, 2010, 28 (1) :162-168.

[2]BELLENTANI S, MARINO M.Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) [J].Ann Hepatol, 2009, 8 (Suppl 1) :s4-s8.

[3]BRUNT EM, TINIAKOS DG.Histopathology of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2010, 16 (42) :5286-5296.

[4]DULAI PS, SINGH S, PATEL J, et al.Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease:systematic review and meta-analysis[J].Hepatology, 2017, 65 (5) :1557-1565.

[5]DAY CP.Natural history of NAFLD:remarkably benign in the absence of cirrhosis[J].Gastroenterology, 2005, 129 (1) :375-378.

[6]LADE A, NOON LA, FRIEDMAN SL.Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer[J].Curr Opin Oncol, 2014, 26 (1) :100-107.

[7]QIU P, TANG MW, MEI X, et al.Clinical characteristics analysis of patients with non-alcoholic fatty liver disease by pathological method[J].J North Sichuan Med Coll, 2015, 30 (2) :182-186. (in Chinese) 邱平, 唐明薇, 梅希, 等.病理学诊断的非酒精性脂肪性肝病患者的临床特点分析[J].川北医学院学报, 2015, 30 (2) :182-186.

[8]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[9] FAN JG.Epidemiology of nonalcoholic fatty liver disease in China[J].Chin J Postgrad Med, 2010, 33 (1) :4-6. (in Chinese) 范建高.中国非酒精性脂肪性肝病的流行病学[J].中国医师进修杂志, 2010, 33 (1) :4-6.

[10]ZHU JZ, ZHOU QY, WANG YM, et al.Prevalence of fatty liver disease and the economy in China:a systematic review[J].World JGastroenterol, 2015, 21 (18) :5695-5706.

[11]KABBANY MN, CONJEEVARAM SELVAKUMAR PK, WATT K, et al.Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the united states:an analysis of national health and nutrition examination survey data[J].Am J Gastroenterol, 2017, 112 (4) :581-587.

[12]ABD EL-KADER SM, AL-SHREEF FM, AL-JIFFRI OH.Biochemical parameters response to weight loss in patients with nonalcoholic steatohepatitis[J].Afr Health Sci, 2016, 16 (1) :242-249.

[13]KASHYAP SR, DIAB DL, BAKER AR, et al.Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort[J].O-besity (Silver Spring) , 2009, 17 (9) :1696-1701.

[14]LOSEKANN A, WESTON AC, DE MATTOS AA, et al.Non-alcoholic steatohepatitis (NASH) :risk factors in morbidly obese patients[J].Int J Mol Sci, 2015, 16 (10) :25552-25559.

[15]CHUNMING L, JIANHUI S, HONGGUANG Z, et al.The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters[J].Turk J Gastroenterol, 2015, 26 (5) :408-416.

[16]GONG XQ, LI SS, CHEN SB, et al.Relationship between ALT, AST and UA levels and liver histology in patients with nonalcoholic fatty liver disease[J].J Med Res, 2016, 45 (8) :90-93. (in Chinese) 龚先琼, 李珊珊, 陈少彬, 等.ALT、AST、UA与非酒精性脂肪肝病理的相关性研究[J].医学研究杂志, 2016, 45 (8) :90-93.

[17]HUANG F, LIU A, FANG H, et al.Serum uric acid levels in non-alcoholic steatosis patients:a meta-analysis[J].Asia Pac JClin Nutr, 2017, 26 (2) :334-342.

[18]LI SF, LIAO XH, YE JZ, et al.Role of uric acid in the development and progression of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2016, 32 (9) :1814-1818. (in Chinese) 李韶丰, 廖献花, 叶俊钊, 等.尿酸在非酒精性脂肪性肝病发生发展中的作用[J].临床肝胆病杂志, 2016, 32 (9) :1814-1818.

[19]HUANG F, LIU A, FANG H, et al.Serum uric acid levels in non-alcoholic steatosis patients:a meta-analysis[J].Asia Pac JClin Nutr, 2017, 26 (2) :334-342.

[20]GU F, DING G, LOU X, et al.Incidence of thyroid diseases in Zhejiang Province, China, after 15 years of salt iodization[J].JTrace Elem Med Biol, 2016, 36:57-64.

[21]JIANG H, TIAN Y, YAN W, et al.The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities[J].Int J Environ Res Public Health, 2016, 13 (4) :442.

[22]XIE N, ZHANG XG, ZHEN P, et al.Association between fatty liver disease and thyroid nodules in people undergoing physical examination[J].Chin J Gerontol, 2015, 35 (21) :6165-6167. (in Chinese) 谢娜, 张旭刚, 甄萍, 等.体检人群脂肪肝与甲状腺结节的相关性[J].中国老年学杂志, 2015, 35 (21) :6165-6167.

[23]RECCIA I, KUMAR J, AKLADIOS C, et al.Non-alcoholic fatty liver disease:a sign of systemic disease[J].Metabolism, 2017, 72:94-108.

[24]DUMAN DG, OZDEMIR F, BIRBEN E, et al.Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis[J].Dig Dis Sci, 2007, 52 (10) :2520-2524.

[25]LI YM.Strengthen researches on risk factors and early diagnosis of nonalcoholic fatty liver[J].Chin J Hepatol, 2013, 21 (11) :805-807. (in Chinese) 厉有名.重视非酒精性脂肪性肝病早期预警研究[J].中华肝脏病杂志, 2013, 21 (11) :805-807.

Relative Articles

[1]	Xiaoxuan XIE, Lina DU, Ziyun GUO, Yan YANG. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2024, 40(1): 199-203. doi: 10.12449/JCH240133
[2]	Long HUANG, Yu CHEN, Qiao WU, Zhongping DUAN. Effect of Shuganning injection on the model of cholestasis - type chlorpromazine - induced liver injury constructed by a new tissue - engineered liver[J]. Journal of Clinical Hepatology, 2022, 38(3): 587-593. doi: 10.3969/j.issn.1001-5256.2022.03.018
[3]	Huaqian XU, Meng WEI, Xue ZHANG, Hai YI, Fangyi FAN, Aiping HUANG, Shanhong TANG. Diffuse large B-cell lymphoma with severe cholestasis as the main manifestation: A case report[J]. Journal of Clinical Hepatology, 2022, 38(12): 2821-2823. doi: 10.3969/j.issn.1001-5256.2022.12.025
[4]	Bo YI, Xue LI, Shanhong TANG. Research advances in the mechanism of abnormal bile acid metabolism caused by gene mutation[J]. Journal of Clinical Hepatology, 2022, 38(9): 2136-2140. doi: 10.3969/j.issn.1001-5256.2022.09.036
[5]	Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1179-1182. doi: 10.3969/j.issn.1001-5256.2022.05.043
[6]	Jing LI, Kuiyang ZHENG, Beibei ZHANG. Mechanism of action of bile acid metabolism in regulating cholestatic liver disease and the research and development of drugs[J]. Journal of Clinical Hepatology, 2021, 37(10): 2482-2487. doi: 10.3969/j.issn.1001-5256.2021.10.048
[7]	WU Rong, LING AiMin. Primary biliary cirrhosis with autoimmune hemolytic anemia: A case report[J]. Journal of Clinical Hepatology, 2020, 36(12): 2795-2797. doi: 10.3969/j.issn.1001-5256.2020.12.030
[8]	Hua HaiYang, Li JianHui, Su Bin, Xuan XiaoYu. Liver subcapsular biliary cyst successfully treated by endoscopic retrograde cholangiopancreatography: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1354-1355. doi: 10.3969/j.issn.1001-5256.2020.06.034
[9]	Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
[10]	Zhou Fang, Li XiaoQin, Wang RuiFeng, Sun Bo. X-linked lymphoproliferative disease type 2 with cholestatic liver disease as initial manifestation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(8): 1811-1814. doi: 10.3969/j.issn.1001-5256.2019.08.034
[11]	Kan YanTing, Yang YongFeng. Role of cholestatic liver disease-related genes in intrahepatic cholestasis of pregnancy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1439-1443. doi: 10.3969/j.issn.1001-5256.2019.07.006
[12]	Song YuanZong. Research advances in the pathogenesis, clinical manifestations, and diagnosis/treatment of sodium-taurocholate cotransporting polypeptide deficiency[J]. Journal of Clinical Hepatology, 2019, 35(8): 1690-1692. doi: 10.3969/j.issn.1001-5256.2019.08.007
[13]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[14]	Zhang XuQian, Zhao ChunShan, Liu WenTian, Wang BangMao, Zhou Lu. Elevated serum GGT level in recovery phase of cholestatic liver disease reveals good prognosis: a case report [J]. Journal of Clinical Hepatology, 2016, 32(4): 774-775. doi: 10.3969/j.issn.1001-5256.2016.04.037
[15]	Shen FeiFei, Lu LunGen. Liver alkaline phosphatase: a marker of cholestasis and bile duct injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 1026-1030. doi: 10.3969/j.issn.1001-5256.2016.05.052
[16]	Li Hua, Li YiMing, Lu Le. Mechanism of α-naphthyl isothiocyanate inducing cholestatic hepatitis: a preliminary study[J]. Journal of Clinical Hepatology, 2016, 32(5): 933-937. doi: 10.3969/j.issn.1001-5256.2016.05.026
[17]	Li Lei, Li Bing, Ding HuiGuo. Effect of ursodeoxycholic acid on bile secretion after endoscopic nasobiliary drainage in patients with cholestatic liver disease of various causes[J]. Journal of Clinical Hepatology, 2016, 32(3): 522-525. doi: 10.3969/j.issn.1001-5256.2016.03.026
[18]	Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
[19]	Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
[20]	Qu Ying, Xu MingYi, Lu LunGen. Current progress in understanding of cholestasis and autoimmune liver diseases——Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(2): 222-225.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	张连峰，杨丽敏. 胸腺肽肠溶片联合聚乙二醇干扰素对慢性肝炎患者的治疗效果及其相关指标的影响. 中国当代医药. 2020(04): 50-52 .
2.	王雪云，孙敏，赵巧云，李红军，王先芝，郑玉山，边城. 聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察. 医学信息. 2020(04): 144-146 .
3.	刘征. 恩替卡韦联合α-干扰素对慢性乙型肝炎患者血清ALT复常率的影响. 淮海医药. 2020(02): 181-183 .
4.	李淑，彭雁忠，胡国信，齐明华，武敬. 聚乙二醇干扰素治疗低水平HBsAg慢性乙肝患者疗效. 中国热带医学. 2020(07): 676-681 .
5.	嵇玮嘉，颜学兵. 聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎的效果及安全性比较. 临床肝胆病杂志. 2019(02): 309-314 . 本站查看
6.	吴明杰. 聚乙二醇干扰素α-2b对慢性乙型肝炎的作用分析. 中国继续医学教育. 2019(12): 142-144 .
7.	张珊，王艺璇，孙静，朱琳，王凤水，邢卉春. 干扰素联合抗病毒治疗对提高核苷（酸）类药物经治慢性乙型肝炎患者表面抗原阴转率的影响. 中华实验和临床感染病杂志(电子版). 2019(04): 273-280 .
8.	郭志勇，贺文娟，裴军芳. 聚乙二醇干扰素α-2a注射液联合替诺福韦酯治疗e抗原阳性慢性乙型肝炎疗效分析. 中国药物与临床. 2019(22): 3944-3946 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2556) PDF downloads(443)

Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors

DOI: 10.3969/j.issn.1001-5256.2017.12.020